Patients with a locally advanced tumor or metastases may benefit from androgen deprivation therapy (ADT) by castration, either surgically with bilateral orchiectomy or medically with luteinizing hormone-releasing hormone (LHRH) agonists, such as leuprolide, goserelin, triptorelin, histrelin, and buserelin, with or without radiation therapy.